Home - Gastroenterology Advisor
Low-FODMAP and Gluten-Free Diets for IBS Improve Physical, Psychological Symptoms
Clinician Insights on How to Manage Semaglutide-Induced …
Sep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
What We Know About Semaglutide Adverse Events and …
Sep 1, 2023 · What Are Other Causes of Gastroparesis? Diabetes is the most common underlying cause of gastroparesis and can damage the vagus nerve, leading to impaired muscular function in the stomach and small intestine. 3 Studies show that the 10-year cumulative incidence of diabetic gastroparesis is estimated to be 5.2% among patients with type 1 diabetes and 1% in patients with type 2 diabetes. 4
Bariatric Surgery for Weight Loss: Gastric Sleeve vs Gastric Bypass
Nov 1, 2024 · References: Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356. doi: 10.1016/j.soard.2022.08.013 American Society for Metabolic and Bariatric Surgery.
Low-FODMAP and Gluten-Free Diets for IBS Improve Physical ...
Dec 3, 2024 · A low-FODMAP diet combined with a gluten-free diet (LF-GFD) can significantly reduce physical and psychological symptoms in irritable bowel syndrome (IBS), according to a systematic review and meta-analysis published in Digestive Diseases and Sciences.. Although dietary interventions have been considered for managing IBS, the effectiveness of a LF-GFD had not been comprehensively assessed ...
Gastroparesis Awareness Month: Updated Guidelines to Treat …
Aug 19, 2022 · The American College of Gastroenterology (ACG) released updated clinical guidelines on managing gastroparesis (GP). The new recommendations were published in The American Journal of Gastroenterology.. GP is characterized by delayed gastric emptying (GE) of solid food in the absence of mechanical obstruction.
Ustekinumab Biosimilar Yesintek Gets FDA Approval
6 days ago · The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases.. Yesintek, formerly known as Bmab 1200, is a human interleukin-12 and -23 antagonist indicated for the treatment of:
Tremfya Approved for Moderate to Severe Ulcerative Colitis
Sep 23, 2024 · The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).. The approval was based on data from the phase 2b/3 QUASAR study (ClinicalTrials.gov Identifier: NCT04033445), which evaluated the safety and efficacy of guselkumab, an interleukin-23 antagonist, in patients with moderately ...
News and Features - Gastroenterology Advisor
The American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy Quality Task force have released updated guidance on quality indicators for colonoscopy.
Chronic Idiopathic Constipation: 10 Recommendations for …
Jun 9, 2023 · The American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) have jointly developed a clinical practice guideline regarding the pharmacological management of patients with chronic idiopathic constipation (CIC), as published in the American Journal of Gastroenterology and Gastroenterology.. The guideline provides 10 evidence-based recommendations for ...